These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38517209)

  • 1. Finding SKYLIGHT for all: fezolinetant efficacy for vasomotor symptoms in subpopulations.
    Reed SD
    Menopause; 2024 Apr; 31(4):245-246. PubMed ID: 38517209
    [No Abstract]   [Full Text] [Related]  

  • 2. Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2).
    Santoro N; Nappi RE; Neal-Perry G; English M; King DD; Yamaguchi Y; Ottery FD
    Menopause; 2024 Apr; 31(4):247-257. PubMed ID: 38517210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fezolinetant (Veozah) for menopausal vasomotor symptoms.
    Med Lett Drugs Ther; 2023 Jun; 65(1679):97-99. PubMed ID: 37339088
    [No Abstract]   [Full Text] [Related]  

  • 4. A Novel Nonhormonal Treatment for Vasomotor Symptoms of Menopause.
    Javernick JA
    Nurs Womens Health; 2024 Feb; 28(1):80-84. PubMed ID: 38161058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fezolinetant: First Approval.
    Lee A
    Drugs; 2023 Aug; 83(12):1137-1141. PubMed ID: 37462862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fezolinetant (Veozah) for the Treatment of Menopause Symptoms.
    Crespo C; Erlich D
    Am Fam Physician; 2024 Mar; 109(3):273-274. PubMed ID: 38574221
    [No Abstract]   [Full Text] [Related]  

  • 7. Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis.
    Elnaga AAA; Alsaied MA; Elettreby AM; Ramadan A
    Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():142-152. PubMed ID: 38640780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats.
    Tahara A; Takamatsu H; Ohtake A; Tanaka-Amino K; Kaku S
    Eur J Pharmacol; 2021 Aug; 905():174207. PubMed ID: 34048742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis.
    Bonga KN; Mishra A; Maiti R; Padhy BM; Meher BR; Srinivasan A
    Obstet Gynecol; 2024 Mar; 143(3):393-402. PubMed ID: 38227939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.
    Depypere H; Timmerman D; Donders G; Sieprath P; Ramael S; Combalbert J; Hoveyda HR; Fraser GL
    J Clin Endocrinol Metab; 2019 Dec; 104(12):5893-5905. PubMed ID: 31415087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fezolinetant in the treatment of vasomotor symptoms associated with menopause.
    Depypere H; Lademacher C; Siddiqui E; Fraser GL
    Expert Opin Investig Drugs; 2021 Jul; 30(7):681-694. PubMed ID: 33724119
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial.
    Yu Q; Ming F; Ma J; Cai Y; Wang L; Ren M; Zhang J; Ma X; Miyazaki K; He W; Wang X
    J Int Med Res; 2024 May; 52(5):3000605241246624. PubMed ID: 38818887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).
    Santoro N; Waldbaum A; Lederman S; Kroll R; Fraser GL; Lademacher C; Skillern L; Young J; Ramael S
    Menopause; 2020 Dec; 27(12):1350-1356. PubMed ID: 32769757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
    Fraser GL; Lederman S; Waldbaum A; Kroll R; Santoro N; Lee M; Skillern L; Ramael S
    Menopause; 2020 Apr; 27(4):382-392. PubMed ID: 32102086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal.
    Gompel A; Stuenkel CA
    Cell Rep Med; 2023 Jun; 4(6):101076. PubMed ID: 37343519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of neurokinin-3 receptor antagonists for the management of vasomotor symptoms of menopause.
    Cieri-Hutcherson NE; Marji EK; Hutcherson TC
    Menopause; 2024 Apr; 31(4):342-354. PubMed ID: 38471077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms.
    Pinkerton JV; Redick DL; Homewood LN; Kaunitz AM
    J Clin Endocrinol Metab; 2023 Oct; 108(11):e1448-e1449. PubMed ID: 37097747
    [No Abstract]   [Full Text] [Related]  

  • 18. Fezolinetant for VMS: a balanced view on efficacy and safety needed - author's reply.
    Chavez MP; Pasqualotto E; Ferreira ROM; Hohl A; de Moraes FCA; Schmidt PHS; Rodrigues ALSO; de Sa JR
    Climacteric; 2024 Aug; 27(4):436-437. PubMed ID: 38973476
    [No Abstract]   [Full Text] [Related]  

  • 19. Neurokinin receptor antagonists as potential nonhormone treatments for vasomotor symptoms.
    Santoro N
    Menopause; 2024 Oct; 31(10):923-925. PubMed ID: 39190331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council.
    Wright AC; Beaudoin FL; McQueen RB; Yeung K; Moradi A; Herron-Smith S; Gutierrez E; Lin GA; Pearson SD
    J Manag Care Spec Pharm; 2023 Jun; 29(6):692-698. PubMed ID: 37276043
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.